Ask the Expert – Clinical Stem Cell Manufacturing

By on June 10, 2013
Ask the Expert

Our Next Session – Clinical Stem Cell Manufacturing – Starts June 10, 2013

There are an increasing number of promising new stem cell therapy candidates in development and many are showing promising results in clinical studies. As more stem cell therapies move from the lab to the clinical setting, there is increased interest in identifying best practices for stem cell manufacturing. Many researchers have specific questions about scaling up stem cell production, optimizing culture media, selecting the right manufacturing equipment, and the regulatory requirements for clinical production. If you have questions regarding stem cell manufacturing, then please join us for a special Ask the Expert session “Clinical Stem Cell Manufacturing.”

Hosting this week’s session is Ronnda Bartel, Ph.D., Chief Scientific Officer, Aastrom Biosciences. Aastrom has successfully moved stem cell therapies from lab scale to clinical manufacturing and we are fortunate to have Ronnda’s expertise for this Ask the Expert session. Ronnda joined Aastrom in 2006 and is responsible for the scientific direction of the company, including research, development and technical operations.  She has more than 20 years of research and product development experience and most recently was executive director, biological research at MicroIslet and vice president, scientific development at StemCells Inc.  Earlier in her career, she was senior principal scientist and director of research at Advanced Tissue Sciences and was involved in the development and approval of some of the first cell-based products approved by the FDA. She has also worked as senior director, science and technology at SRS Capital, LLC evaluating life science investments and has held positions in clinical development, drug delivery, business development and manufacturing. Ronnda holds a PhD in biochemistry from the University of Kansas, has completed postdoctoral work at the University of Michigan and received a BA in chemistry and biology from Tabor College.

For more information, please see Ronnda’s previous guest blog “From Product Candidate to Product – The Road to Commercialization in Regenerative Medicine.

View Topic / Ask Question

Leave a Reply

Your email address will not be published. Required fields are marked *